Teva Pharmaceutical Industries Limited (TEVA) is making waves in the healthcare sector, particularly among hedge funds who are increasingly buying into this small-cap stock. With shares trading at $16.89 as of May 14th and a forward P/E ratio of 6.47, Teva is catching the attention of investors looking for value in the pharmaceutical industry.
Teva Pharmaceuticals is the world’s largest generic drugmaker and is currently undergoing a significant transformation under the leadership of CEO Richard Francis. The company’s recent Q1 2025 results showcased its ninth consecutive quarter of revenue growth, with a 2% year-over-year increase to $3.89 billion. Adjusted EPS of $0.52 exceeded expectations, and free cash flow surged an impressive 238% year-over-year.
One of the key drivers of Teva’s growth is its focus on innovation, as demonstrated by the success of its novel drug portfolio. Drugs like Austedo, Ajovy, and Uzedy are experiencing strong growth and are expected to contribute significantly to Teva’s revenue in the coming years. The company’s generics business, while still a core component, is also experiencing growth and provides stability and scale to the overall business.
Teva’s cost-cutting initiative, known as the “Acceleration Phase,” aims to reduce costs by $700 million by 2027 and improve operational efficiency. This, coupled with a focus on deleveraging and mitigating operational risks, positions Teva for continued success in the pharmaceutical industry.
Financially, Teva has made significant progress in reducing its debt and improving its margins, with a goal of bringing net debt-to-EBITDA below 2x. With a revitalized strategy, strong momentum, and an undervalued stock, Teva presents an attractive investment opportunity with potential upside in the next 12 months.
While Teva may not be among the most popular stocks among hedge funds, it is certainly gaining attention for its promising growth prospects. Investors looking for a compelling AI stock with high return potential may want to consider Teva as a value play in the pharmaceutical sector.
